Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05024552
Other study ID # MCC-20752
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date August 23, 2021
Est. completion date August 2025

Study information

Verified date June 2024
Source H. Lee Moffitt Cancer Center and Research Institute
Contact Jhada-Kai Hunter
Phone 813-745-0286
Email Jhada-Kai.Hunter@moffitt.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study combines vyxeos and gilteritinib in patients with relapsed or refractory FLT3-mutated acute myeloid leukemia. Vyxeos and gilteritinib will be given as induction therapy. Those patients entering a complete remission or a complete remission with incomplete blood count recovery will be allowed to proceed to consolidation therapy with vyxeos and gilteritinib. Those patients who do not proceed to an allogeneic stem cell transplant for any reason are able to enter the maintenance phase of this trial using daily gilteritinib


Recruitment information / eligibility

Status Recruiting
Enrollment 22
Est. completion date August 2025
Est. primary completion date August 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Provision of signed and dated informed consent form - Stated willingness to comply with all study procedures and availability for the duration of the study - Eastern Cooperative Oncology Group (ECOG) performance status =2 - FLT3-ITD or FLT3-TKD mutated AML (non-M3) in 1st or greater relapse or refractory to at least one prior line of AML directed therapy - FLT3 testing must be confirmed at the time of disease relapse - Adequate organ function - Left ventricular ejection fraction (LVEF) =50% - Prior anthracycline exposure =368 mg/m2 daunorubicin (or equivalent) - Ability to take oral medication and willingness to adhere to the medication regimen - For females of reproductive potential: use of highly effective contraception including double barrier methods (condoms with spermicidal jelly or foam and diaphragm with spermicidal jelly or foam), oral, depo provera, or injectable contraceptives, intrauterine devices and tubal ligation. - For females of reproductive potential: negative serum or urine pregnancy test with a sensitivity of at least 50mIU/mL within 10 days and again within 24 hours of beginning study treatment - For males of reproductive potential: use of condoms - Breastfeeding mothers must agree to discontinue nursing - Patients who have relapsed after and allogeneic stem cell transplant must have controlled grade =2 GVHD. Immunosuppression with tacrolimus or sirolimus is allowed at stable or tapering doses. Exclusion Criteria: - Patients may not be receiving any other investigational agents - Patients with documented central nervous system involvement of AML - Progression of AML while on prior gilteritinib therapy - Patients must not have evidence of GI tract abnormalities that would alter the absorption of oral medications - Major surgery within two weeks of first dose of study drug. Patients must have recovered from the effects of any surgery performed greater than two weeks prior - WBC count =50,000 at the time study treatment begins. Use of hydroxyurea to maintain WBC <50,000 is allowed up to the time that study treatment begins - Predicted inability to tolerate standard induction chemotherapy - Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements - No other malignancies in addition to AML that are currently requiring treatment with the exception of: 1) basal cell or squamous cell carcinoma or the skin; 2) carcinoma in situ of the cervix or breast; 3) a history of breast cancer that is currently being managed with adjuvant endocrine therapy - Grade =3 acute or chronic graft versus host disease after allogeneic stem cell transplant. No steroids for GVHD are allowed.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Gilteritinib
Gilteritinib is an oral inhibitor of FLT3-ITD and FLT3-TKD. Dose cohort 1 will receive 120mg daily on days 6-19 of induction and days 4-17 of re-induction and consolidation
Vyxeos
Vyxeos is a liposomal encapsulation of cytarabine and daunorubicin. It is given as an intravenous infusion over 90 minutes on days 1, 3 and 5 of induction and days 1 and 3 of re-induction and consolidation. The induction and reinduction dose is 44mg/m2 daunorubicin and 100mg/m2 of cytarabine with each infusion. The consolidation dose is 29mg/m2 daunorubicin and 65mg/m2 of cytarabine with each dose.

Locations

Country Name City State
United States Moffitt Cancer Center Tampa Florida

Sponsors (2)

Lead Sponsor Collaborator
H. Lee Moffitt Cancer Center and Research Institute Jazz Pharmaceuticals

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Maximum Tolerated Dose (MTD) Dose escalation will determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of Vyxeos plus Gilteritinib. The MTD is the highest dose of the combination therapy that dose not cause unacceptable side effects. Up to 18 months
Secondary Complete Remission Rate Rate of complete remission (CR) and complete remission with incomplete blood count recovery (CRi). The definition of CR and CRi is based on the European LeukemiaNet 2017 Response Criteria Up to 18 months
Secondary Event free survival (EFS) Event free survival is determined as the duration of time from start of treatment to the time of cancer recurrence. Up to 18 months
Secondary Overall survival (OS) Overall survival is defined as the duration of time from start of treatment to the time of death from any cause or date of last contact. Up to 5 years
See also
  Status Clinical Trial Phase
Recruiting NCT05596981 - The Gut Microbiome in FLT3-ITD+ AML Undergoing Allo-HSCT With Or Without Sorafenib Maintenance After Allo-HSCT
Recruiting NCT05596968 - The Gut Microbiome and Sorafenib Maintenance Therapy in FLT3-ITD Positive AML After Allo-HSCT
Terminated NCT01028716 - Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Phase 2
Not yet recruiting NCT05876832 - A Study of XY0206 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory AML With FLT3-ITD-Mutation (ALIVE) Phase 3
Completed NCT03735875 - Venetoclax and Quizartinib in Treating Patients With FLT3-mutated Recurrent or Refractory Acute Myeloid Leukemia Phase 1/Phase 2
Completed NCT01578109 - Sorafenib Tosylate Before and After Donor Bone Marrow Transplant in Treating Patients With Acute Myeloid Leukemia Phase 1
Completed NCT04788420 - Influence of Co-existing Mutations on Sorafenib Maintenance Therapy After Allo-HSCT for Patients With FLT3-ITD AML
Recruiting NCT06222580 - SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation Phase 1
Active, not recruiting NCT03333486 - Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer Phase 2
Terminated NCT02634827 - Midostaurin and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia and FLT3 Mutation Phase 2
Completed NCT01760655 - Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies Phase 2
Recruiting NCT04174612 - AML Patients Bearing FLT3 Mutations Based on Peripheral Blast Clearance Phase 3
Completed NCT01253070 - Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia Phase 2